Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SUTRO BIOPHARMA, INC.STRO · Entity 5797 | Director · CEO | March 05, 2025 | March 07, 2025 |
| Social Capital Suvretta Holdings Corp. IVDNAD · Entity 123913 | Director | September 07, 2022 | September 09, 2022 |
| Vaxcyte, Inc.PCVX · Entity 1164 | Director | December 09, 2020 | December 11, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SUTRO BIOPHARMA, INC.
Report date March 05, 2025 · Filed March 07, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 292,531 |
Ending reported balance
After 2025-03-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-03-05 · Exercise / conversion · Acquired 18,750 · Balance 299,239 Row 2 · 2025-03-05 · Tax withholding · Disposed 6,708 · Balance 292,531 F1: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. |
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security · Expires 2025-03-05 | Direct | 0 |
Reported balance
After 2025-03-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-03-05 · Exercise / conversion · Disposed 18,750 · Balance 0 F3: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F4: The RSUs vest as to 1/4th of the total shares annually beginning on March 5, 2022, subject to continued service through each vesting date. |
| Common StockSEC Table I · non-derivative | IndirectBy William J. Newell Family Trust DTD 03/15/2019 | 116,525 |
Reported balance
Holding disclosure · report date 2025-03-05 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 116,525 F2: The securities are held of record by the reporting person as trustee of the William J. Newell Family Trust DTD 03/15/2019. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person.
F2: The securities are held of record by the reporting person as trustee of the William J. Newell Family Trust DTD 03/15/2019.
F3: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.
F4: The RSUs vest as to 1/4th of the total shares annually beginning on March 5, 2022, subject to continued service through each vesting date.
Social Capital Suvretta Holdings Corp. IV
Report date September 07, 2022 · Filed September 09, 2022
This filing explicitly reported no securities owned.
Vaxcyte, Inc.
Report date December 09, 2020 · Filed December 11, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 66,684 |
Reported balance
After 2020-12-09 transaction · row 1
1 source rowRow 1 · 2020-12-09 · Grant · Acquired 22,228 · Balance 66,684 F1: Shares acquired by the reporting person from Sutro Biopharma, Inc. pursuant to the Sutro Biopharma, Inc. 2017 Call Option Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares acquired by the reporting person from Sutro Biopharma, Inc. pursuant to the Sutro Biopharma, Inc. 2017 Call Option Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 05, 2025 Filed Mar 7, 2025 16:14 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-007405 · form4-03072025_090322.xml · derivative · entry 4 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,750 shares Expires 2025-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on March 5, 2022, subject to continued service through each vesting date. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 16:14 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 6,708 | $1.36 | $9,122.88 |
DisclosureSEC source: 0001415889-25-007405 · form4-03072025_090322.xml · nonDerivative · entry 2 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 292,531 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 16:14 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-007405 · form4-03072025_090322.xml · nonDerivative · entry 1 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 299,239 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 16:09 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 31,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-007183 · form4-03062025_090325.xml · derivative · entry 4 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,125 Underlying: Common Stock · 31,125 shares Expires 2026-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on March 4, 2023, subject to continued service through each vesting date. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 16:09 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 11,136 | $1.42 | $15,813.12 |
DisclosureSEC source: 0001415889-25-007183 · form4-03062025_090325.xml · nonDerivative · entry 2 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 280,489 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 16:09 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 31,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-007183 · form4-03062025_090325.xml · nonDerivative · entry 1 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 291,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 18:32 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 41,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006690 · form4-03042025_110305.xml · derivative · entry 6 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,250 Underlying: Common Stock · 41,750 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F5 · derivative.exercise_date: The RSUs vest as to 1/4th of the total award annually beginning on March 1, 2025, subject to continued service through each vesting date. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 18:32 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 23,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006690 · form4-03042025_110305.xml · derivative · entry 5 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,500 Underlying: Common Stock · 23,750 shares Expires 2027-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on March 1, 2024, subject to continued service through each vesting date. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 18:32 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 25,203 | $1.59 | $40,072.77 |
DisclosureSEC source: 0001415889-25-006690 · form4-03042025_110305.xml · nonDerivative · entry 3 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 260,500 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 18:32 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 41,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006690 · form4-03042025_110305.xml · nonDerivative · entry 2 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 285,703 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 18:32 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 23,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006690 · form4-03042025_110305.xml · nonDerivative · entry 1 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 243,953 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 16:31 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-007188 · form4-03072024_090300.xml · derivative · entry 6 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 18,750 shares Expires 2025-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F6 · derivative.exercise_date: The RSUs vest as to 1/4th of the total award annually beginning on March 5, 2022, subject to continued service through each vesting date. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 16:31 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Units (RSUs) · Derivative | 130,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-007188 · form4-03072024_090300.xml · derivative · entry 5 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,500 Underlying: Common Stock · 130,500 shares Expires 2028-03-01 F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F5 · derivative.exercise_date: The RSUs vest as to 1/4th of the total award annually beginning on March 1, 2025, subject to continued service through each vesting date. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 16:31 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (Right to Buy Common Stock) · Derivative | 174,000 | $0.00 Strike: $4.54 | $0.00 |
DisclosureSEC source: 0001415889-24-007188 · form4-03072024_090300.xml · derivative · entry 4 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 174,000 Underlying: Common Stock · 174,000 shares Expires 2034-03-05 F3 · derivative.exercise_date: The option vests as to 2.0833% of the total award monthly, beginning on April 1, 2024, with 100% of the award being vested and exercisable on March 1, 2028, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 16:31 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 6,690 | $4.54 | $30,372.60 |
DisclosureSEC source: 0001415889-24-007188 · form4-03072024_090300.xml · nonDerivative · entry 2 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 220,203 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 16:31 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-007188 · form4-03072024_090300.xml · nonDerivative · entry 1 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 226,893 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2024 Filed Mar 22, 2024 16:28 UTC Amendment | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Units (RSUs) · Derivative | 167,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-008954 · form4a-03222024_080335.xml · derivative · entry 1 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 167,000 Underlying: Common Stock · 167,000 shares Expires 2028-03-01 F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F2 · derivative.exercise_date: The RSUs vest as to 1/4th of the total award annually beginning on March 1, 2025, subject to continued service through each vesting date. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 16:28 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 31,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-007039 · form4-03062024_090306.xml · derivative · entry 4 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,250 Underlying: Common Stock · 31,125 shares Expires 2026-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The RSUs vest as to 1/4th of the total award annually beginning on March 4, 2023, subject to continued service through each vesting date. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 16:28 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 11,105 | $4.79 | $53,192.95 |
DisclosureSEC source: 0001415889-24-007039 · form4-03062024_090306.xml · nonDerivative · entry 2 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 208,143 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 16:28 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 31,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-007039 · form4-03062024_090306.xml · nonDerivative · entry 1 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 219,248 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 16:40 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 23,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-006725 · form4-03052024_090358.xml · derivative · entry 4 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,250 Underlying: Common Stock · 23,750 shares Expires 2027-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The RSU award vests as to 1/4th of the total award annually beginning on March 1, 2024, subject to continued service through each vesting date. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 16:40 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 8,559 | $4.95 | $42,367.05 |
DisclosureSEC source: 0001415889-24-006725 · form4-03052024_090358.xml · nonDerivative · entry 2 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 188,123 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 16:40 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 23,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-006725 · form4-03052024_090358.xml · nonDerivative · entry 1 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 196,682 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 16:29 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 13,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-002072 · form4-01312024_090125.xml · derivative · entry 4 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,750 shares Expires 2024-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on January 29, 2021, subject to continued service through each vesting date. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 16:29 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 5,634 | $4.99 | $28,113.66 |
DisclosureSEC source: 0001415889-24-002072 · form4-01312024_090125.xml · nonDerivative · entry 2 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 172,932 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 16:29 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 13,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-002072 · form4-01312024_090125.xml · nonDerivative · entry 1 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 178,566 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 16:56 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016809 · doc4.xml · derivative · entry 8 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 18,750 shares Expires 2025-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F7 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on March 5, 2022, subject to continued service through each vesting date. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 16:56 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 31,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016809 · doc4.xml · derivative · entry 7 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,375 Underlying: Common Stock · 31,125 shares Expires 2026-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F6 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on March 4, 2023, subject to continued service through each vesting date. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 16:56 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Unit (RSU) · Derivative | 95,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016809 · doc4.xml · derivative · entry 6 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires 2027-03-01 F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F5 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on March 1, 2024, subject to continued service through each vesting date. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 16:56 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy Common Stock) · Derivative | 125,000 | $0.00 Strike: $5.79 | $0.00 |
DisclosureSEC source: 0001209191-23-016809 · doc4.xml · derivative · entry 5 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2033-02-28 F4 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning on April 1, 2023, with 100% of the total shares vested and exercisable on March 1, 2027, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 16:56 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 17,246 | $5.79 | $99,854.34 |
DisclosureSEC source: 0001209191-23-016809 · doc4.xml · nonDerivative · entry 3 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,816 F2 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 16:56 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 18,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016809 · doc4.xml · nonDerivative · entry 2 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,062 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 16:56 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 31,125 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016809 · doc4.xml · nonDerivative · entry 1 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,312 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 17:31 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 13,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-005765 · doc4.xml · derivative · entry 4 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,750 Underlying: Common Stock · 13,750 shares Expires 2024-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F5 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on January 29, 2021, subject to continued service through each vesting date. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 17:31 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 5,600 | $7.50 | $42,000.00 |
DisclosureSEC source: 0001209191-23-005765 · doc4.xml · nonDerivative · entry 2 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,187 F2 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 17:31 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 13,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-005765 · doc4.xml · nonDerivative · entry 1 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,787 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 10,577 shares of common stock transferred from the Newell Family Revocable Trust DTD 08/14/2008. Read SEC document |
| March 14, 2022 Filed Mar 15, 2022 19:00 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | PurchaseCommon Stock | 10,000 | $7.75 | $77,508.00 |
DisclosureSEC source: 0001209191-22-018969 · doc4.xml · nonDerivative · entry 1 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By William J. Newell Family Trust DTD 03/15/2019 Disclosed balance after: 116,525 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.68 to $7.85 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are held of record by the reporting person as trustee of the William J. Newell Family Trust DTD 03/15/2019. Read SEC document |
| March 05, 2022 Filed Mar 7, 2022 19:25 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-016856 · doc4.xml · derivative · entry 7 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,250 Underlying: Common Stock · 18,750 shares Expires 2025-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F7 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on March 5, 2022, subject to continued service through each vesting date. Read SEC document |
| March 05, 2022 Filed Mar 7, 2022 19:25 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 6,483 | $8.17 | $52,966.11 |
DisclosureSEC source: 0001209191-22-016856 · doc4.xml · nonDerivative · entry 2 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,460 F2 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document |
| March 05, 2022 Filed Mar 7, 2022 19:25 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 18,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-016856 · doc4.xml · nonDerivative · entry 1 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,943 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. Read SEC document |
| March 04, 2022 Filed Mar 7, 2022 19:25 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Unit (RSU) · Derivative | 124,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-016856 · doc4.xml · derivative · entry 6 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,500 Underlying: Common Stock · 124,500 shares Expires 2026-03-04 F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F6 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on March 4, 2023, subject to continued service through each vesting date. Read SEC document |
| March 04, 2022 Filed Mar 7, 2022 19:25 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy Common Stock) · Derivative | 166,000 | $0.00 Strike: $8.17 | $0.00 |
DisclosureSEC source: 0001209191-22-016856 · doc4.xml · derivative · entry 5 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,000 Underlying: Common Stock · 166,000 shares Expires 2032-03-03 F5 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning on April 4, 2022, with 100% of the total shares vested and exercisable on March 4, 2026, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| January 29, 2022 Filed Feb 1, 2022 20:37 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 13,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006128 · doc4.xml · derivative · entry 5 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Stock · 13,750 shares Expires 2025-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F5 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on January 29, 2021, subject to continued service through each vesting date. Read SEC document |
| January 29, 2022 Filed Feb 1, 2022 20:37 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 5,278 | $10.39 | $54,838.42 |
DisclosureSEC source: 0001209191-22-006128 · doc4.xml · nonDerivative · entry 2 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,193 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document |
| January 29, 2022 Filed Feb 1, 2022 20:37 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 13,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006128 · doc4.xml · nonDerivative · entry 1 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,471 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 30, 2021 Filed Jan 3, 2022 18:28 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | OtherCommon Stock | 1,863 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-000329 · doc4.xml · nonDerivative · entry 2 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By William J. Newell Family Trust DTD 03/15/2019 Disclosed balance after: 106,525 F3 · shares: Represents shares received as a liquidating distribution from Taluswood. F4 · ownership.nature: The securities are held of record by the reporting person as trustee of the William J. Newell Family Trust DTD 03/15/2019. Read SEC document |
| December 30, 2021 Filed Jan 3, 2022 18:28 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | OtherCommon Stock | 26,091 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-000329 · doc4.xml · nonDerivative · entry 1 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Taluswood Partners, L.P. Disclosed balance after: 0 F1 · kind: Represents pro rata distributions to the limited partners of Taluswood Partners, L.P. ("Taluswood"). F2 · ownership.nature: The reporting person is the general partner of Taluswood. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| September 24, 2021 Filed Sep 28, 2021 18:58 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 25,253 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-057981 · doc4.xml · derivative · entry 7 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,253 shares Expires 2021-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F6 · derivative.exercise_date: The RSUs vest as to 1/3rd of the total shares annually beginning on September 26, 2019, subject to continued service through each vesting date. Read SEC document |
| September 24, 2021 Filed Sep 28, 2021 18:58 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 13,219 | $19.23 | $254,201.37 |
DisclosureSEC source: 0001209191-21-057981 · doc4.xml · nonDerivative · entry 4 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,721 F2 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document |
| September 24, 2021 Filed Sep 28, 2021 18:58 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 25,253 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-057981 · doc4.xml · nonDerivative · entry 3 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,940 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.